Comparative characteristics of proton pump inhibitor effectiveness in the treatment of gastric ulcer and duodenal ulcer was written by Balitska, Olesya P.;Germanyuk, Tamara A.;Hryhoruk, Yuliia M.;Ivko, Tatiana I.;Tomashevska, Yuliia O.;Koval, Vasyl M.;Polishchuk, Yuliia M.;Hutsol, Viktoriia V.;Artemchuk, Myhailo A.. And the article was included in Current Issues in Pharmacy and Medical Sciences in 2020.Synthetic Route of C18H20N3NaO3S The following contents are mentioned in the article:
Materials and methods: The materials of this research are the results of 86 original studies on the effectiveness of proton pump inhibitors anal. Methods. Descriptive, statistical, retrospective. Results and Conclusion. According to the clin. random researches, Omeprazole preparations are not included in the list due to proven better effectiveness of Esomeprazole drugs. Moreover, lansoprazole drugs are not included according to proven short-acid inhibitory effect. In addition, the brand of mentioned above preparation does not exist on the pharmaceutical market of Ukraine. Furthermore, rabeprazole preparations are presented in the research by Pariet (brand) and by the effective generic Barol, while pantoprazole preparations are represented in the research by Kontrolok (brand) and by the generic Pultset, as well as by Nolpaza. Herein, the Pantosan effect was not significantly different from the effect of Pultset and Nolpaza, but the preparation is much more expensive. In terms of efficiency (%), 4 wk repair of mucosal defects was carried out by way of the following treatment regimens: Barol + Amoxicillin + Clarythromycin (90.9卤6.2), Pariet + Amoxicillin + Clarythromycin (83卤2.6), Kontrolok + Amoxicillin + Clarythromycin (100卤1.3), Pultset + Amoxicillin + Clarythromycin (88卤4.1), Nolpaza + Amoxicillin + Clarythromycin (72卤4.1), Ezolonh + Amoxicillin + Clarythromycin (87.7卤3.8), Neksium + Amoxicillin + Clarythromycin (96.1卤3.1). This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Synthetic Route of C18H20N3NaO3S).
Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Synthetic Route of C18H20N3NaO3S
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem